A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
第一作者:
Panayiotis,Panayiotidis
第一单位:
Laikon General Hospital and National and Kapodistrian University of Athens, Athens, Greece.
作者:
医学主题词
成年人(Adult);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);淋巴瘤, B细胞, 边缘区(Lymphoma, B-Cell, Marginal Zone);Waldenstrom巨球蛋白血症(Waldenstrom Macroglobulinemia)
DOI
10.1080/10428194.2021.2015765
PMID
35045765
发布时间
2022-06-22
- 浏览1
Leukemia & lymphoma
1058-1069页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



